LP
KERX

LMR Partners’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

LMR Partners’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-18,824
Closed -$125K – 552
2016
Q2 		$125K Buy
+18,824
New +$105K 0.02% 384

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

LMR Partners's KERX Position: Q3 2016 in Review

LMR Partners sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2016, closing a stake of 18,824 shares — an estimated $125K sold.

LMR Partners first reported a position in KERX in Q2 2016 and held it in 1 quarter. The position peaked at $125K in Q2 2016. 116 funds tracked by Wall St. Rank hold KERX as of Q3 2016.

  • LMR Partners reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • LMR Partners sold 18,824 Keryx Biopharmaceuticals Inc shares in Q3 2016, an estimated $125K.
  • LMR Partners first reported a position in Keryx Biopharmaceuticals Inc in Q2 2016 and held it in 1 quarter.
  • LMR Partners's Keryx Biopharmaceuticals Inc position peaked at $125K in Q2 2016.
  • 116 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2016.

Based on LMR Partners's 13F filing for Q3 2016, filed 1 Nov 2016.